Dare Bioscience Sets Nov 10 Vote on 45% Warrant Dilution
DARE sits 22% above its 52-week low of $0.69 on light trading volume (0.2× avg).
Summary
Dare Bioscience's definitive proxy sets a November 10 vote on warrant exercise that could dilute existing shareholders by 45.4%. The company needs the potential $12.4 million in proceeds as it battles Nasdaq delisting and going-concern doubts.
Key Events · Corporate Governance and Compliance · DARE
-
Warrant Exercise Vote Set for Nov 10
A special meeting is scheduled for November 10, 2026, to approve exercise of 8,934,345 warrants from the August 2026 financing. The record date is September 30, 2026, with 19,669,083 shares outstanding.
-
45.4% Potential Dilution
If all warrants are exercised, 8,934,345 new shares would be issued — approximately 45.4% of shares outstanding on September 30, 2026. Existing shareholders' voting power and ownership would be correspondingly reduced.
-
$12.4M Potential Proceeds at Risk
Full cash exercise of all warrants would generate approximately $12.4 million in gross proceeds. If shareholders reject the proposal, the company loses access to this capital and must call meetings every 60 days until approval is obtained.
-
Nasdaq Delisting and Going Concern Backdrop
This vote comes amid two Nasdaq delisting notices (July 13 and September 28, 2026) and going-concern doubt disclosed in the Q2 2026 10-Q. The warrant exercise proceeds are critical for the company's survival.
Analysis · DARE · Life Sciences
Shareholders are being asked to approve the exercise of 8.9 million warrants from the August 2026 financing. If approved, the warrants would add approximately 45.4% to the current share count — a massive overhang for a company already fighting Nasdaq delisting and going-concern warnings. The vote is scheduled for November 10, 2026, and the company must hold it by November 15 under its purchase agreement. If shareholders reject the proposal, the company loses access to up to $12.4 million in potential warrant exercise proceeds and must keep calling meetings every 60 days, draining cash and management attention.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1563 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DARE was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4M. The 52-week trading range was $0.69 to $3.78. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.